CASTLE BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
CASTLE BIOSCIENCES, INC. (CSTL) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $8.38 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-11.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2021-03-11
- CASTLE BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-12-31 was $0.00.
- CASTLE BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-09-30 was $0.00.
- CASTLE BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-06-30 was $0.00.
- CASTLE BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-03-31 was $8.38M.
- CASTLE BIOSCIENCES, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $8.38M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month as first filed | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $8.38M 10-K · filed 2021-03-11 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $8.38M 10-Q · filed 2020-11-09 | $8.38M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $8.38M 10-Q · filed 2020-08-10 | $8.38M 10-Q · filed 2019-09-03 | |||
| 2019-03-31 | $8.38M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |